Combining serotonin and cannabinoid drugs improved a schizophrenia-related brain function in mice

Combining a serotonin 5-HT2A blocker with a CB1 receptor blocker improved prepulse inhibition (a brain function disrupted in schizophrenia) more than either drug alone in mice.

Marques, Adriana M et al.·Psychopharmacology·2020·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-02711Animal StudyPreliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Neither the CB1 agonist WIN 55,212-2 nor the CB1 inverse agonist rimonabant alone affected prepulse inhibition (PPI) or blocked MK-801-induced PPI deficits. However, combining the 5-HT2A antagonist volinanserin with rimonabant significantly improved PPI in both normal and MK-801-treated mice, suggesting a synergistic interaction between serotonin and cannabinoid systems.

Key Numbers

Volinanserin + rimonabant combination increased PPI in both control and MK-801-treated mice; neither cannabinoid drug alone affected PPI.

How They Did This

Animal study in male Swiss mice testing combinations of cannabinoid drugs (WIN 55,212-2, rimonabant) and serotonin drugs (8-OH-DPAT, volinanserin) in an MK-801-induced PPI disruption model relevant to schizophrenia.

Why This Research Matters

Current antipsychotic medications have significant side effects. Finding that combined serotonin-cannabinoid modulation works better than either alone opens a new avenue for drug combination strategies in psychotic disorders.

The Bigger Picture

This supports the idea that complex mental illnesses may respond better to multi-target drug approaches than single-mechanism treatments. The serotonin-endocannabinoid interaction could be particularly relevant for schizophrenia.

What This Study Doesn't Tell Us

Animal model; MK-801-induced PPI disruption is only one aspect of schizophrenia pathology; rimonabant has been withdrawn from clinical use due to psychiatric side effects; only male mice used.

Questions This Raises

  • ?Could newer CB1 antagonists without rimonabant side effects achieve the same synergy?
  • ?Would this combination approach work in human psychosis?

Trust & Context

Key Stat:
Volinanserin + rimonabant combination improved PPI; neither cannabinoid drug alone did
Evidence Grade:
Preliminary: animal behavioral pharmacology study with synthetic compounds.
Study Age:
Published 2020.
Original Title:
Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.
Published In:
Psychopharmacology, 237(6), 1643-1655 (2020)
Database ID:
RTHC-02711

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is prepulse inhibition?

A brain function where a weak stimulus reduces the startle response to a subsequent stronger stimulus. It is consistently disrupted in schizophrenia and used as a model for studying antipsychotic drug targets.

Why did the combination work but not the individual drugs?

The authors suggest that blocking CB1 receptors potentiated the effect of 5-HT2A blockade, implying these systems interact to control sensory gating processes disrupted in psychosis.

Read More on RethinkTHC

Cite This Study

RTHC-02711·https://rethinkthc.com/research/RTHC-02711

APA

Marques, Adriana M; Macena, Michele V; Cardoso, Aline R; Hammes, Camila S O; Pinheiro, Fernanda M L; Castro, Newton G; Neves, Gilda A. (2020). Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.. Psychopharmacology, 237(6), 1643-1655. https://doi.org/10.1007/s00213-020-05485-0

MLA

Marques, Adriana M, et al. "Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.." Psychopharmacology, 2020. https://doi.org/10.1007/s00213-020-05485-0

RethinkTHC

RethinkTHC Research Database. "Effects of combined 5-HT2A and cannabinoid receptor modulati..." RTHC-02711. Retrieved from https://rethinkthc.com/research/marques-2020-effects-of-combined-5ht2a

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.